The Tumor–Immune Interface for Next-Generation Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 363

Special Issue Editor


E-Mail Website
Guest Editor
Molecular Engineering for Cellular Imaging and Reprogramming, University of Southern California, Los Angeles, CA, USA
Interests: immunotherapy; optogenetics; synthetic biology; epigenetics; live cell imaging; FRET biosensors

Special Issue Information

Dear Colleagues,

Immunotherapy has revolutionized the treatment of cancers, especially for blood cancers. Nonetheless, the application of immunotherapy in solid tumors is far more challenging. One of the key challenges is the ability of tumors to evade immune surveillance by creating an immunosuppressive microenvironment. Tumor cells can secrete cytokines and chemokines that attract immune-suppressive cells such as regulatory T cells and myeloid-derived suppressor cells, which inhibit anti-tumor immune responses. In addition, tumors can express ligands that interact with immune-checkpoint receptors on T cells, leading to T cell exhaustion and dysfunction. To overcome these challenges, next-generation immunotherapies aim to modulate the tumor–immune interface by either enhancing anti-tumor immune responses or inhibiting immunosuppressive mechanisms. Overall, the tumor–immune interface is a complex and dynamic system that plays a crucial role in tumor progression and response to immunotherapy. Developing next-generation immunotherapies that can effectively modulate the tumor–immune interface is an active area of research and holds promise for improving outcomes for cancer patients. This Special Issue of Cancers therefore encompasses original research articles and comprehensive reviews on all aspects of the tumor–immune interface for next-generation immunotherapy.

Dr. Ziliang Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immunomodulation
  • checkpoint blockade
  • tumor microenvironment
  • CAR
  • TCR
  • tumor vaccines
  • synthetic biology
  • biomedical engineering

Published Papers

This special issue is now open for submission.
Back to TopTop